CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis
Open Access
- 1 March 2006
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 13 (3), 538-547
- https://doi.org/10.1016/j.ymthe.2005.11.008
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosisMolecular Therapy, 2005
- Recombinant AAV Viral Vectors Pseudotyped with Viral Capsids from Serotypes 1, 2, and 5 Display Differential Efficiency and Cell Tropism after Delivery to Different Regions of the Central Nervous SystemMolecular Therapy, 2004
- Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosisNeurobiology of Disease, 2004
- Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosisNeurobiology of Disease, 2004
- Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transferGene Therapy, 2001
- Genetics of the neuronal ceroid lipofuscinosesCurrent Opinion in Genetics & Development, 2000
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yieldGene Therapy, 1999
- Novel Tools for Production and Purification of Recombinant Adenoassociated Virus VectorsHuman Gene Therapy, 1998
- Efficient selection for high-expression transfectants with a novel eukaryotic vectorGene, 1991
- Inborn Errors of Mucopolysaccharide MetabolismScience, 1970